Recurrent Energy, a subsidiary of Canadian Solar Inc., held a tour and ribbon-cutting ceremony at Bayou Galion Solar, a 127-MW DC solar project located in Northeast Louisiana. The project commenced ...

To train with default parameters on the tinyshakespeare corpus, run python train.py. To access all the parameters use python train.py --help.

An endoscopical and histological study was carried out in 114 patients, treated by 'curative' resection of the terminal ileum and part of the colon for Crohn's disease, in order to study the natural ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

You can read more about sound event detection literature here. This method was first proposed in 'Sound event detection using spatial features and convolutional recurrent neural network'. It recently ...

Alexandre Carpentier, Carthera reaches this milestone as it prepares to conduct the largest clinical trial ever using ultrasound for the temporary opening of the blood-brain-barrier (BBB) in patients ...

THE WEEK’S MOST POPULAR SONGS RANKED BY ADULT CONTEMPORARY RADIO AIRPLAY DETECTIONS, AS MEASURED BY MEDIABASE AND PROVIDED BY LUMINATE. Teddy Swims Last week Weeks at no. 1 Weeks on chart J.E ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

The trial (NCT05902169) is the world’s first randomized, multicentric, two-arm pivotal trial of BBB opening prior to chemotherapy injection in recurrent glioblastoma patients. Notably, the trial makes ...

today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver ...

A copy of the R&D Day presentation can be found here. About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...